Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 24 September 2009, Vol. 114, No. 13, pp. 2730-2732.
Prepublished online as a Blood First Edition Paper on July 28, 2009; DOI 10.1182/blood-2009-04-217521.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Table
Right arrow All Versions of this Article:
blood-2009-04-217521v1
114/13/2730    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Purdue, M. P.
Right arrow Articles by Rothman, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Purdue, M. P.
Right arrow Articles by Rothman, N.
Related Collections
Right arrow Lymphoid Neoplasia
Right arrow Brief Reports
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

LYMPHOID NEOPLASIA

Brief report

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

Mark P. Purdue1, Qing Lan1, Otoniel Martinez-Maza2, Martin M. Oken3, William Hocking4, Wen-Yi Huang1, Dalsu Baris1, Betty Conde5, and Nathaniel Rothman1

1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD; 2 Departments of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles; 3 Department of Medicine, University of Minnesota, Minneapolis; 4 Department of Hematology/Oncology, Marshfield Clinic, WI; and 5 Protein Expression Laboratory, Advanced Technology Program, SAIC-Frederick Inc, National Cancer Institute, Frederick, MD

Prediagnostic serum concentration of soluble CD30 (sCD30), a marker for chronic B-cell stimulation, has been associated with increased risk of developing AIDS-related non-Hodgkin lymphoma (NHL) in a recent study of HIV+ patients. To investigate among healthy persons whether serum sCD30 is associated with NHL risk, we carried out a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. There was a strong dose-response relationship between prediagnostic sCD30 concentration and NHL risk among 234 cases and 234 individually matched controls (odds ratio [95% confidence interval] for second, third, and fourth quartiles vs first quartile: 1.4 [0.8-2.6], 2.2 [1.2-4.1], 4.1 [2.2-7.8]; Ptrend < .001), which persisted among cases diagnosed 6 to 10 years after providing a blood sample. Given that a similar relationship has been observed among HIV+ patients, our findings suggest that chronic B-cell stimulation may be an important mechanism involved in B-cell lymphomagenesis among severely immunocompromised and healthy populations alike.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020